Gujarat Terce Laboratories returned to profitability in FY26, reporting a net profit of ₹2.20 crore, a significant jump from a loss in FY25. However, revenues declined.
Gujarat Terce Laboratories has reported a net profit of ₹2.20 crore for the fiscal year 2026, marking a significant turnaround from a net loss of ₹0.98 crore in FY25. In the fourth quarter of FY26, the company achieved a net profit of ₹0.10 crore, recovering from a loss of ₹3.39 crore in the same period last year. Reader Takeaway: Profitability returns, but revenue decline and margin pressure remain concerns. ## What just happened Gujarat Terce Laboratories announced its financial results for the fourth quarter and full fiscal year 2026. The company reported a net profit of ₹2.20 crore for FY26, compared to a net loss of ₹0.98 crore in FY25. For Q4 FY26, the reported PAT was ₹0.10 crore against a loss of ₹3.39 crore in Q4 FY25. ## Why this matters The return to profitability, especially for the full fiscal year, is a key positive for shareholders. It suggests that the company's efforts to strengthen its fundamentals and improve earnings quality are yielding results. The reported significant strengthening of net worth also indicates a healthier financial base. ## The backstory FY26 was characterized by a strategic focus on strengthening the company's fundamentals and improving the quality of earnings. Management indicated that the business is undergoing structural improvements. ## What changes now The company has demonstrated its ability to achieve profitability. Investors will be looking for sustained earnings growth and a reversal of the recent revenue decline. ## Risks to watch Revenue has declined, with Q4 FY26 revenue down 8% and full-year FY26 revenue down 5% compared to the previous year. EBITDA margins have also contracted, with Q4 FY26 EBITDA margin at 3.24% compared to 9.25% in Q4 FY25. ## Peer comparison (No specific peer comparison data available in the filing). ## Context metrics (time-bound) * **Q4 FY26 Revenue:** ₹11.3993 crore (down 8% YoY) * **FY26 Revenue:** ₹47.4727 crore (down 5% YoY) * **Q4 FY26 EBITDA Margin:** 3.24% (vs 9.25% in Q4 FY25) * **FY26 EBITDA Margin:** 7.66% (vs 8.35% in FY25) * **FY26 Reported PAT:** ₹2.2017 crore (vs -₹0.9787 crore in FY25) * **Net Worth:** Strengthened by over 50% in FY26. ## What to track next Investors will be keen to see if Gujarat Terce Laboratories can reverse the revenue decline and improve its margins while maintaining profitability in the upcoming fiscal year. The execution of its strategy to enhance brand equity and field productivity will be crucial.
Get stock alerts instantly on WhatsApp
Quarterly results, bulk deals, concall updates and major announcements delivered in real time.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.
